CD101, CD101 molecule, 9398

N. diseases: 15; N. variants: 2
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0877445
Disease: Candidemia
Candidemia 		0.040 Biomarker disease BEFREE Rezafungin (CD101) is a novel echinocandin antifungal agent currently in clinical development for the treatment of candidemia and invasive candidiasis. 29555631 2018
CUI: C0877445
Disease: Candidemia
Candidemia 		0.040 Biomarker disease BEFREE CD101 is currently being evaluated as a once-weekly intravenous (i.v.) infusion for the treatment of candidemia and invasive candidiasis. 29133552 2018
CUI: C0877445
Disease: Candidemia
Candidemia 		0.040 Biomarker disease BEFREE CD101 IV is a novel echinocandin with distinctive pharmacokinetic properties that is being developed as a once-weekly treatment for candidemia and invasive candidiasis. 27919901 2017
CUI: C0877445
Disease: Candidemia
Candidemia 		0.040 Biomarker disease BEFREE CD101, a novel echinocandin with a long plasma half-life and enhanced stability, is in development for once-weekly IV administration for the treatment of candidemia and invasive candidiasis. 28826987 2017
CUI: C0153252
Disease: Systemic candidiasis
Systemic candidiasis 		0.030 Biomarker disease BEFREE Rezafungin (CD101) is a novel echinocandin antifungal agent currently in clinical development for the treatment of candidemia and invasive candidiasis. 29555631 2018
CUI: C0153252
Disease: Systemic candidiasis
Systemic candidiasis 		0.030 Biomarker disease BEFREE CD101 is currently being evaluated as a once-weekly intravenous (i.v.) infusion for the treatment of candidemia and invasive candidiasis. 29133552 2018
CUI: C1609535
Disease: Invasive Candidiasis
Invasive Candidiasis 		0.030 Biomarker disease BEFREE Rezafungin (CD101) is a novel echinocandin antifungal agent currently in clinical development for the treatment of candidemia and invasive candidiasis. 29555631 2018
CUI: C1609535
Disease: Invasive Candidiasis
Invasive Candidiasis 		0.030 Biomarker disease BEFREE CD101 is currently being evaluated as a once-weekly intravenous (i.v.) infusion for the treatment of candidemia and invasive candidiasis. 29133552 2018
CUI: C0153252
Disease: Systemic candidiasis
Systemic candidiasis 		0.030 Biomarker disease BEFREE CD101, a novel echinocandin with a long plasma half-life and enhanced stability, is in development for once-weekly IV administration for the treatment of candidemia and invasive candidiasis. 28826987 2017
CUI: C1609535
Disease: Invasive Candidiasis
Invasive Candidiasis 		0.030 Biomarker disease BEFREE CD101, a novel echinocandin with a long plasma half-life and enhanced stability, is in development for once-weekly IV administration for the treatment of candidemia and invasive candidiasis. 28826987 2017
CUI: C0011854
Disease: Diabetes Mellitus, Insulin-Dependent
Diabetes Mellitus, Insulin-Dependent 		0.020 Biomarker disease BEFREE As compared to CD101+/+ NOD.B6 Idd10 donors, adoptive T cell transfers from CD101-/- NOD.B6 Idd10 mice increased T1D frequency in lymphopenic NOD scid and NOD.B6 Idd10 scid recipients. 31199784 2019
CUI: C0700345
Disease: Candidiasis, Vulvovaginal
Candidiasis, Vulvovaginal 		0.020 Biomarker disease BEFREE CD101 Topical Compared With Oral Fluconazole for Acute Vulvovaginal Candidiasis: A Randomized Controlled Trial. 30893271 2019
CUI: C0011854
Disease: Diabetes Mellitus, Insulin-Dependent
Diabetes Mellitus, Insulin-Dependent 		0.020 GeneticVariation disease BEFREE Whole-exome sequencing and genome-wide copy-number analysis of familial cases showed co-segregation of the p.V863L substitution in CD101, the human homolog of an autoimmune diabetes gene in the non-obese diabetic mouse, with type 1 diabetes. 27888582 2017
CUI: C0700345
Disease: Candidiasis, Vulvovaginal
Candidiasis, Vulvovaginal 		0.020 AlteredExpression disease BEFREE To evaluate the antifungal activity of CD101 against clinical VVC isolates of Candida spp., including azole-resistant strains, at pH 4. 28158577 2017
CUI: C1262313
Disease: Invasive Fungal Infections
Invasive Fungal Infections 		0.020 AlteredExpression group BEFREE Given its low clearance, long half-life, and wide tissue distribution, CD101 once weekly is expected to provide appropriate systemic levels for treatment and prevention of invasive fungal infections. 28137817 2017
CUI: C1262313
Disease: Invasive Fungal Infections
Invasive Fungal Infections 		0.020 Biomarker group BEFREE CD101 was as active as the other echinocandins against common fungal organisms recovered from patients with invasive fungal infections. 28052853 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.010 Biomarker group BEFREE High coexpression of CD38/CD101 on peripheral PD-1<sup>+</sup>CD8<sup>+</sup> T cells or tumor-infiltrating lymphocytes (TILs) was found to be most significantly correlated with Tumor/Node/Metastasis (T/N/M) classification and clinical stage, in contrast PD-1<sup>+</sup>CD8<sup>+</sup> T cells could not correlate with T classification. 30689488 2019
CUI: C1832661
Disease: ANOPHTHALMIA AND PULMONARY HYPOPLASIA
ANOPHTHALMIA AND PULMONARY HYPOPLASIA 		0.010 Biomarker disease BEFREE Our data suggest that CD38/CD101 might represent a more helpful biomarker than PD-1 alone for diagnosis and prognosis of PDAC. 30689488 2019
CUI: C0011847
Disease: Diabetes
Diabetes 		0.010 GeneticVariation disease BEFREE Nucleotide substitutions in CD101, the human homolog of a diabetes susceptibility gene in non-obese diabetic mouse, in patients with type 1 diabetes. 27888582 2017
CUI: C0011849
Disease: Diabetes Mellitus
Diabetes Mellitus 		0.010 GeneticVariation group BEFREE Nucleotide substitutions in CD101, the human homolog of a diabetes susceptibility gene in non-obese diabetic mouse, in patients with type 1 diabetes. 27888582 2017
CUI: C0009319
Disease: Colitis
Colitis 		0.010 Biomarker disease BEFREE Thus, CD101 deficiency is a novel marker for progressive colitis and potential target for therapeutic intervention. 26813346 2016
CUI: C0021390
Disease: Inflammatory Bowel Diseases
Inflammatory Bowel Diseases 		0.010 AlteredExpression group BEFREE Finally, in patients with IBD a reduced CD101 expression on peripheral and intestinal monocytes and CD4(+) T cells correlated with enhanced IL-17 production and disease activity. 26813346 2016
CUI: C0267375
Disease: Chronic colitis
Chronic colitis 		0.010 Biomarker disease BEFREE Using a T-cell transfer model of chronic colitis, we found that in recipients of naïve T cells from CD101(+/+) donors up to 30% of the recovered lymphocytes expressed CD101, correlating with an increased interleukin (IL)-2-mediated FoxP3 expression. 26813346 2016
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.010 Biomarker disease BEFREE Future research is needed into the possible role of NOS1 and CD101 for PC. 21467233 2011
CUI: C0346647
Disease: Malignant neoplasm of pancreas
Malignant neoplasm of pancreas 		0.010 Biomarker disease BEFREE Future research is needed into the possible role of NOS1 and CD101 for PC. 21467233 2011